<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>15(1)</volume><submitter>Santa Paola S</submitter><pubmed_abstract>Aromatic L-amino acid decarboxylase deficiency (AADCd) is a rare autosomal recessive neurometabolic disorder caused by AADC deficiency, an enzyme encoded by the &lt;i>DDC&lt;/i> gene. Since the enzyme is involved in the biosynthesis of serotonin and dopamine, its deficiency determines the lack of these neurotransmitters, but also of norepinephrine and epinephrine. Onset is early and the key signs are hypotonia, movement disorders (oculogyric crises, dystonia and hypokinesia), developmental delay and autonomic dysfunction. Taiwan is the site of a potential founder variant (IVS6+4A>T) with a predicted incidence of 1/32,000 births, while only 261 patients with this deficit have been described worldwide. Actually, the number of affected persons could be greater, given that the spectrum of clinical m</pubmed_abstract><journal>Genes</journal><pagination>134</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC10815063</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Aromatic L-Amino Acid Decarboxylase Deficiency: A Genetic Screening in Sicilian Patients with Neurological Disorders.</pubmed_title><pmcid>PMC10815063</pmcid><pubmed_authors>Brighina F</pubmed_authors><pubmed_authors>Santa Paola S</pubmed_authors><pubmed_authors>Lo Giudice M</pubmed_authors><pubmed_authors>Lupica A</pubmed_authors><pubmed_authors>Scuderi C</pubmed_authors><pubmed_authors>Pettinato R</pubmed_authors><pubmed_authors>Di Blasi FD</pubmed_authors><pubmed_authors>Di Stefano V</pubmed_authors><pubmed_authors>Borgione E</pubmed_authors><pubmed_authors>Giuliano M</pubmed_authors></additional><is_claimable>false</is_claimable><name>Aromatic L-Amino Acid Decarboxylase Deficiency: A Genetic Screening in Sicilian Patients with Neurological Disorders.</name><description>Aromatic L-amino acid decarboxylase deficiency (AADCd) is a rare autosomal recessive neurometabolic disorder caused by AADC deficiency, an enzyme encoded by the &lt;i>DDC&lt;/i> gene. Since the enzyme is involved in the biosynthesis of serotonin and dopamine, its deficiency determines the lack of these neurotransmitters, but also of norepinephrine and epinephrine. Onset is early and the key signs are hypotonia, movement disorders (oculogyric crises, dystonia and hypokinesia), developmental delay and autonomic dysfunction. Taiwan is the site of a potential founder variant (IVS6+4A>T) with a predicted incidence of 1/32,000 births, while only 261 patients with this deficit have been described worldwide. Actually, the number of affected persons could be greater, given that the spectrum of clinical m</description><dates><release>2024-01-01T00:00:00Z</release><publication>2024 Jan</publication><modification>2025-04-21T15:58:06.949Z</modification><creation>2025-04-21T15:58:06.949Z</creation></dates><accession>S-EPMC10815063</accession><cross_references><pubmed>38275615</pubmed><doi>10.3390/genes15010134</doi></cross_references></HashMap>